

**TOXICOLOGICAL PROFILE FOR  
OTTO FUEL II AND ITS COMPONENTS**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry

**June 1995**

**DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

### **UPDATE STATEMENT**

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and the Environmental Protection Agency (EPA) and in support of Department of Defense information needs. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, when known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are significant to protect public health will be identified by ATSDR and the EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) When appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that might present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). Section 211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities.

Section 2704(b) of Title 10 of the U. S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological profile for each substance on the list provided by the Secretary of Defense under subsection (b).

**Foreword**

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

## CONTRIBUTORS

### **CHEMICAL MANAGER(S)/AUTHOR(S):**

Henry Abadin, M.S.P.H.

ATSDR, Division of Toxicology, Atlanta, GA

Fernando Lladós, Ph.D.

Research Triangle Institute, Research Triangle Park, NC

### **THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:**

1. Green Border Review. Green Bonier review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.





## PEER REVIEW

A peer review panel was assembled for Otto Fuel II and its components. The panel consisted of the following members:

- 1 . Steven Godin, Ph.D., DABT, Research Scientist, Drug Metabolism, CEPHALON, Inc., West Chester, Pennsylvania;
- 2 . Dr. Arthur Gregory, Private Consultant, Techt Enterprises, Sterling, Virginia; and
- 3 . Dr. Richard Stewart, Private Consultant, Racine, Wisconsin.

These experts collectively have knowledge of Otto Fuel II and its components' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)( 13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
PEER REVIEW .....	ix
LIST OF FIGURES .....	xv
LIST OF TABLES .....	xvii
<b>1. PUBLIC HEALTH STATEMENT .....</b>	<b>1</b>
1.1 WHAT ARE OTTO FUEL II AND ITS COMPONENTS? .....	2
1.2 WHAT HAPPENS TO OTTO FUEL II AND ITS COMPONENTS WHEN THEY ENTER THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO OTTO FUEL II AND ITS COMPONENTS? .....	3
1.4 HOW CAN THE COMPONENTS OF OTTO FUEL II ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN OTTO FUEL II AND ITS COMPONENTS AFFECT MY HEALTH? .....	4
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO OTTO FUEL II AND ITS COMPONENTS? .....	6
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	7
1.8 WHERE CAN I GET MORE INFORMATION? .....	7
<b>2. HEALTH EFFECTS .....</b>	<b>9</b>
2.1 INTRODUCTION .....	9
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	9
2.2.1 Inhalation Exposure .....	10
2.2.1.1 Death .....	11
2.2.1.2 Systemic Effects .....	12
2.2.1.3 Immunological and Lymphoreticular Effects .....	32
2.2.1.4 Neurological Effects .....	33
2.2.1.5 Reproductive Effects .....	36
2.2.1.6 Developmental Effects .....	37
2.2.1.7 Genotoxic Effects .....	37
2.2.1.8 Cancer .....	37
2.2.2 Oral Exposure .....	38
2.2.2.1 Death .....	38
2.2.2.2 Systemic Effects .....	46
2.2.2.3 Immunological and Lymphoreticular Effects .....	49
2.2.2.4 Neurological Effects .....	49
2.2.2.5 Reproductive Effects .....	50
2.2.2.6 Developmental Effects .....	50
2.2.2.7 Genotoxic Effects .....	51
2.2.2.8 Cancer .....	52

2.2.3	Dermal Exposure	52
2.2.3.1	Death	52
2.2.3.2	Systemic Effects	53
2.2.3.3	Immunological and Lymphoreticular Effects	62
2.2.3.4	Neurological Effects	63
2.2.3.5	Reproductive Effects	64
2.2.3.6	Developmental Effects	65
2.2.3.7	Genotoxic Effects	65
2.2.3.8	Cancer	66
2.3	TOXICOKINETICS	66
2.3.1	Absorption	67
2.3.1.1	Inhalation Exposure	67
2.3.1.2	Oral Exposure	67
2.3.1.3	Dermal Exposure	68
2.3.2	Distribution	68
2.3.2.1	Inhalation Exposure	68
2.3.2.2	Oral Exposure	69
2.3.2.3	Dermal Exposure	69
2.3.3	Metabolism	69
2.3.3.1	Inhalation Exposure	69
2.3.3.2	Oral Exposure	70
2.3.3.3	Dermal Exposure	70
2.3.3.4	Other Routes of Exposure	70
2.3.4	Excretion	71
2.3.4.1	Inhalation Exposure	71
2.3.4.2	Oral Exposure	73
2.3.4.3	Dermal Exposure	73
2.3.4.4	Other Routes of Exposure	73
2.3.5	Mechanisms of Action	74
2.4	RELEVANCE TO PUBLIC HEALTH	75
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	88
2.5.1	Biomarkers Used to Identify or Quantify Exposure to Otto Fuel II and Its Components	89
2.5.2	Biomarkers Used to Characterize Effects Caused by Otto Fuel II and Its Components	91
2.6	INTERACTIONS WITH OTHER CHEMICALS	93
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	93
2.8	METHODS FOR REDUCING TOXIC EFFECTS	96
2.8.1	Reducing Peak Absorption Following Exposure	96
2.8.2	Reducing Body Burden	96
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	97
2.9	ADEQUACY OF THE DATABASE	98
2.9.1	Existing Information on Health Effects of Otto Fuel II and Its Components	98
2.9.2	Identification of Data Needs	104
2.9.3	Ongoing Studies	115
3.	CHEMICAL AND PHYSICAL INFORMATION	117
3.1	CHEMICAL IDENTITY	117
3.2	PHYSICAL AND CHEMICAL PROPERTIES	117

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	121
4.1 PRODUCTION .....	121
4.2 IMPORT/EXPORT .....	122
4.3 USE .....	122
4.4 DISPOSAL .....	123
5. POTENTIAL FOR HUMAN EXPOSURE .....	125
5.1 OVERVIEW .....	125
5.2 RELEASES TO THE ENVIRONMENT .....	126
5.2.1 Air .....	126
5.2.2 Water .....	126
5.2.3 Soil .....	128
5.3 ENVIRONMENTAL FATE .....	128
5.3.1 Transport and Partitioning .....	128
5.3.2 Transformation and Degradation .....	129
5.3.2.1 Air .....	129
5.3.2.2 Water .....	129
5.3.2.3 Sediment and Soil .....	131
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	132
5.4.1 Air .....	132
5.4.2 Water .....	132
5.4.3 Sediment and Soil .....	132
5.4.4 Other Environmental Media .....	132
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	133
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	134
5.7 ADEQUACY OF THE DATABASE .....	134
5.7.1 Identification of Data Needs .....	135
5.7.2 Ongoing Studies .....	137
6. ANALYTICAL METHODS .....	139
6.1 BIOLOGICAL SAMPLES .....	139
6.2 ENVIRONMENTAL SAMPLES .....	141
6.3 ADEQUACY OF THE DATABASE .....	147
6.3.1 Identification of Data Needs .....	147
6.3.2 Ongoing Studies .....	148
7. REGULATIONS AND ADVISORIES .....	149
8. REFERENCES .....	151
9. GLOSSARY .....	163
 APPENDICES	
A. USER'S GUIDE .....	A-1
B. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	B-1



## LIST OF FIGURES

2-1	Levels of Significant Exposure to Propylene Glycol Dinitrate - Inhalation . . . . .	20
2-2	Levels of Significant Exposure to Propylene Glycol Dinitrate - Oral . . . . .	41
2-3	Levels of Significant Exposure to Dibutyl Sebacate - Oral . . . . .	45
2-4	Proposed Metabolic Pathway for Propylene Glycol Dinitrate . . . . .	72
2-5	Existing Information on Health Effects of Otto Fuel II . . . . .	99
2-6	Existing Information on Health Effects of Propylene Glycol Dinitrate . . . . .	100
2-7	Existing Information on Health Effects of 2-Nitrodiphenylamine . . . . .	101
2-8	Existing Information on Health Effects of Dibutyl Sebacate . . . . .	102
5-1	Frequency of NPL Sites with Otto Fuel II Contamination . . . . .	127





**LIST OF TABLES**

2-1	Levels of Significant Exposure to Propylene Glycol Dinitrate - Inhalation . . . . .	13
2-2	Levels of Significant Exposure to Propylene Glycol Dinitrate - Oral . . . . .	40
2-3	Levels of Significant Exposure to Dibutyl Sebacate - Oral . . . . .	42
2-4	Levels of Significant Exposure to Otto Fuel II - Dermal . . . . .	54
2-5	Levels of Significant Exposure to Propylene Glycol Dinitrate - Dermal . . . . .	55
2-6	Genotoxicity of Otto Fuel II and its Components - <i>In Vivo</i> . . . . .	86
2-7	Genotoxicity of Otto Fuel II and its Components - <i>In Vitro</i> . . . . .	87
3-1	Chemical Identity of Otto Fuel II and its Components . . . . .	118
3-2	Physical and Chemical Properties of Otto Fuel II and its Components . . . . .	119
6-1	Analytical Methods for Determining Otto Fuel II and its Components in Biological Samples . . . . .	140
6-2	Analytical Methods for Determining Otto Fuel II and its Components in Environmental Samples . . . . .	142
7-1	Regulations and Guidelines Applicable to Otto Fuel II and its Components . . . . .	150